Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP7 | Q93009 | 10/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.33 |
| ▸ | CFTR | P13569 | 1/20 | 0.33 |
| ▸ | GPR6 | P46095 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5253860 | 0.92 | USP7 (0.43) | USP7SLC6A2SLC6A3FSCN1BDKRB1 | |
| SCHEMBL5257545 | 0.92 | USP7 (0.37) | USP7SLC6A2SLC6A3FSCN1BDKRB1 | |
| SCHEMBL5524576 | 0.90 | USP7 (0.40) | USP7SLC6A2SLC6A3FSCN1BDKRB1 | |
| SCHEMBL5526756 | 0.90 | USP7 (0.40) | USP7SLC6A2SLC6A3FSCN1GPR6 | |
| SCHEMBL5534369 | 0.89 | USP7 (0.40) | USP7SLC6A2SLC6A3FSCN1CFTR | |
| SCHEMBL5253315 | 0.88 | USP7 (0.38) | USP7SLC6A2SLC6A3FSCN1MEN1 | |
| SCHEMBL5518804 | 0.88 | USP7 (0.47) | USP7SLC6A2SLC6A3FSCN1BDKRB1 | |
| SCHEMBL14376162 | 0.86 | MEN1 (0.36) | USP7FSCN1MEN1KMT2ACFTR | |
| SCHEMBL5254813 | 0.85 | USP7 (0.39) | USP7SLC6A2SLC6A3FSCN1GPR6 | |
| SCHEMBL5255956 | 0.85 | USP7 (0.36) | USP7SLC6A2SLC6A3FSCN1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232644-A1 | 1-(2,4-difluorobenzyl)-N-hydroxy-3-{[3-(methylsulfonyl)pyrrolidin-1-yl]methyl}-1H-pyrrolo[2,3-c]pyridine-5-carboxamide;acquired immunodeficiency syndrome (\"AIDS\"), and AIDS related complex (\"ARC\") | PFIZER INC. | 2007-10-04 | — | — | US | claimed |
| US-20070232644-A1 | 1-(2,4-difluorobenzyl)-N-hydroxy-3-{[3-(methylsulfonyl)pyrrolidin-1-yl]methyl}-1H-pyrrolo[2,3-c]pyridine-5-carboxamide;acquired immunodeficiency syndrome (\"AIDS\"), and AIDS related complex (\"ARC\") | PFIZER INC. | 2007-10-04 | — | — | US | disclosed |
| EP-1802619-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | Pfizer, Inc. (US) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006027694-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER INC. (US) | 2006-03-16 | — | — | WO | disclosed |
| WO-2006027694-A1 | INHIBITORS OF THE HIV INTEGRASE ENZYME | PFIZER INC. (US) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232644-A1 | 1-(2,4-difluorobenzyl)-N-hydroxy-3-{[3-(methylsulfonyl)pyrrolidin-1-yl]methyl}-1H-pyrrolo[2,3-c]pyridine-5-carboxamide;acquired immunodeficiency syndrome (\"AIDS\"), and AIDS related complex (\"ARC\") | AP1M1, AP1G1, AP3B1 | USP7 4732/4885SLC6A2 3268/4885SLC6A3 2502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.